157 related articles for article (PubMed ID: 35933937)
61. Extranodal extension is a strong prognosticator in HPV-positive oropharyngeal squamous cell carcinoma.
Bauer E; Mazul A; Chernock R; Rich J; Jackson RS; Paniello R; Pipkorn P; Oppelt P; Gay H; Daly M; El-Mofty S; Thorstad W; Adkins D; Zevallos J
Laryngoscope; 2020 Apr; 130(4):939-945. PubMed ID: 31077394
[TBL] [Abstract][Full Text] [Related]
62. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
63. Evaluating the impact of smoking on disease-specific survival outcomes in patients with human papillomavirus-associated oropharyngeal cancer treated with transoral robotic surgery.
Roden DF; Hobelmann K; Vimawala S; Richa T; Fundakowski CE; Goldman R; Luginbuhl A; Curry JM; Cognetti DM
Cancer; 2020 Jan; 126(9):1873-1887. PubMed ID: 32032441
[TBL] [Abstract][Full Text] [Related]
64. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.
Settle K; Posner MR; Schumaker LM; Tan M; Suntharalingam M; Goloubeva O; Strome SE; Haddad RI; Patel SS; Cambell EV; Sarlis N; Lorch J; Cullen KJ
Cancer Prev Res (Phila); 2009 Sep; 2(9):776-81. PubMed ID: 19641042
[TBL] [Abstract][Full Text] [Related]
65. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
[TBL] [Abstract][Full Text] [Related]
66. Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region.
Ren J; Yang W; Su J; Ren X; Fazelzad R; Albert T; Habbous S; Goldstein DP; de Almeida JR; Hansen A; Jang R; Bratman SV; Hope A; Chen R; Wang J; Xu Y; Cheng D; Zhao Y; Xu W; Liu G
Int J Cancer; 2019 Sep; 145(6):1465-1474. PubMed ID: 30698281
[TBL] [Abstract][Full Text] [Related]
67. Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
Chargi N; Bril SI; Swartz JE; Wegner I; Willems SM; de Bree R
Oral Oncol; 2020 Feb; 101():104519. PubMed ID: 31855705
[TBL] [Abstract][Full Text] [Related]
68. Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy.
Lee LJ; Howitt B; Catalano P; Tanaka C; Murphy R; Cimbak N; DeMaria R; Bu P; Crum C; Horowitz N; Matulonis U; Viswanathan AN
Gynecol Oncol; 2016 Aug; 142(2):293-8. PubMed ID: 27210818
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of HPV status in the re-irradiation of recurrent and second primary cancers of the head and neck.
Velez MA; Wang PC; Hsu S; Chin R; Beron P; Abemayor E; St John M; Chen AM
Am J Otolaryngol; 2018; 39(3):257-260. PubMed ID: 29433815
[TBL] [Abstract][Full Text] [Related]
70. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
71. Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation.
Gorphe P; Chekkoury Idrissi Y; Tao Y; Schernberg A; Ou D; Temam S; Casiraghi O; Blanchard P; Mirghani H
Papillomavirus Res; 2018 Jun; 5():32-37. PubMed ID: 29253748
[TBL] [Abstract][Full Text] [Related]
72. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.
Salazar CR; Smith RV; Garg MK; Haigentz M; Schiff BA; Kawachi N; Anayannis N; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
Head Neck Pathol; 2014 Mar; 8(1):77-87. PubMed ID: 24002971
[TBL] [Abstract][Full Text] [Related]
73. Biomarkers of HPV in head and neck squamous cell carcinoma.
Liang C; Marsit CJ; McClean MD; Nelson HH; Christensen BC; Haddad RI; Clark JR; Wein RO; Grillone GA; Houseman EA; Halec G; Waterboer T; Pawlita M; Krane JF; Kelsey KT
Cancer Res; 2012 Oct; 72(19):5004-13. PubMed ID: 22991304
[TBL] [Abstract][Full Text] [Related]
74. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
[TBL] [Abstract][Full Text] [Related]
75. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
[TBL] [Abstract][Full Text] [Related]
76. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
[TBL] [Abstract][Full Text] [Related]
77. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
78. Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma.
Alluri KC; Tahari AK; Wahl RL; Koch W; Chung CH; Subramaniam RM
AJR Am J Roentgenol; 2014 Oct; 203(4):897-903. PubMed ID: 25247958
[TBL] [Abstract][Full Text] [Related]
79. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
[TBL] [Abstract][Full Text] [Related]
80. Oncologic outcomes of selective neck dissection in HPV-related oropharyngeal squamous cell carcinoma.
Zenga J; Jackson RS; Graboyes EM; Sinha P; Lindberg M; Martin EJ; Ma D; Thorstad WL; Rich JT; Moore EJ; Haughey BH
Laryngoscope; 2017 Mar; 127(3):623-630. PubMed ID: 27634021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
